Journal of the American Academy of Dermatology · 2021
Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
King Brett A, Mesinkovska Natasha Atanaskova, Craiglow Brittany, Kindred Chesahna, Ko Justin, McMichael Amy, Shapiro Jerry, Goh Carolyn, Mirmirani Paradi, Tosti Antonella, Hordinsky Maria, Huang Kathie P, Castelo-Soccio Leslie, Bergfeld Wilma, Paller Amy S, Mackay-Wiggan Julian, Glashofer Marc, Aguh Crystal, Piliang Melissa, Yazdan Pedram, Lo Sicco Kristen, Cassella James V, Koenigsberg Justine, Ahluwalia Gurpreet, Ghorayeb Eric, Fakharzadeh Steven, Napatalung Lynne, Gandhi Kavita, DeLozier Amy M, Nunes Fabio P, Senna Maryanne M
Аннотация
BACKGROUND: The current classification for alopecia areata (AA) does not provide a consistent assessment of disease severity.
OBJECTIVE: To develop an AA severity scale based on expert experience.
METHODS: A modified Delphi process was utilized. An advisory group of 22 AA clinical experts from the United States was formed to develop this AA scale. Representatives from the pharmaceutical industry provided feedback during its development.
RESULTS: Survey responses were used to draft severity criteria, aspiring to develop a simple scale that may be easily applied in clinical practice. A consensus vote was held to determine the final AA severity statement, with all AA experts agreeing to adopt the proposed scale.
LIMITATIONS: The scale is a static assessment intended to be used in clinical practice and not clinical trials.
CONCLUSION: The final AA disease severity scale, anchored in the extent of hair loss, captures key features commonly used by AA experts in clinical practice. This scale will better aid clinicians in appropriately assessing severity in patients with this common disease.
OBJECTIVE: To develop an AA severity scale based on expert experience.
METHODS: A modified Delphi process was utilized. An advisory group of 22 AA clinical experts from the United States was formed to develop this AA scale. Representatives from the pharmaceutical industry provided feedback during its development.
RESULTS: Survey responses were used to draft severity criteria, aspiring to develop a simple scale that may be easily applied in clinical practice. A consensus vote was held to determine the final AA severity statement, with all AA experts agreeing to adopt the proposed scale.
LIMITATIONS: The scale is a static assessment intended to be used in clinical practice and not clinical trials.
CONCLUSION: The final AA disease severity scale, anchored in the extent of hair loss, captures key features commonly used by AA experts in clinical practice. This scale will better aid clinicians in appropriately assessing severity in patients with this common disease.